What is FULC stock price today?

FULC (Fulcrum Therapeutics Inc) stock is trading at $8.29 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is FULC stock going up or down today?

FULC stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy FULC stock now?

The decision to buy FULC depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is FULC a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for FULC based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is FULC stock overvalued or undervalued?

Use our DCF valuation calculator to determine if FULC is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is FULC's P/E ratio?

P/E ratio data for FULC will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is FULC's market cap?

FULC (Fulcrum Therapeutics Inc) has a market capitalization of $0.55 billion, making it a small-cap stock.

What is FULC's price to book ratio?

FULC trades at a price-to-book (P/B) ratio of 1.58, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does FULC pay dividends?

FULC does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is FULC's dividend yield?

FULC does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is FULC stock a good long-term investment?

FULC's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is FULC's revenue growth rate?

FULC has shown revenue growth of -1.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for FULC are available on our dashboard with complete income statement analysis.

What are the risks of investing in FULC?

Key risks for FULC include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does FULC compare to its competitors?

Compare FULC to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize FULC's performance and positioning.

What is FULC's stock price target for 2026?

Our AI model provides price targets for FULC based on fundamental analysis: Bull case $10.78 (+30%), Base case $9.53 (+15%), Bear case $7.46 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about FULC?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for FULC. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is FULC's next earnings report?

FULC reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

FULC - Fulcrum Therapeutics Inc

NYSE * Health Care * Biotechnology

$8.29

+$0.30 (+3.75%)

About Fulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Key Statistics

Market Cap

$552.12M

P/B Ratio

1.58

EPS

$-1.18

Revenue Growth

-1.0%

Employees

How FULC Compares to Peers

FULC is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
FULC(This stock)	$552.12M	N/A	-1%	0.0%	-
AMGNAmgen Inc	$191.53B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Fulcrum Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.fulcrumtx.com
Sector: Health Care
Industry: Biotechnology

FULC - Fulcrum Therapeutics Inc

About Fulcrum Therapeutics Inc

FULC Key Statistics

How FULC Compares to Peers

Fulcrum Therapeutics Inc Company Information

FULC Lician Score

FULC Financial Snowflake

Upcoming Events for FULC